Barry Douglas, the General Counsel of Tango Therapeutics, Inc. (NASDAQ:TNGX), recently executed stock sales totaling $16,369. The transactions occurred on February 4 and February 5, with shares sold ...

Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine stock tumbled late Thursday after the company issued lackluster guidance for its bread-and-butter product, Ingrezza.Please watch the video at Investors.com - How To Buy Stocks: ...

Neurocrine Biosciences Inc. NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.

Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.